Krishna Gundabolu, MD
Hematology & Oncology · Omaha, NENPI 1710250899
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.7%. Among hematology & oncology clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $973.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$14K
- Biomarin Pharmaceutical Inc.$11K
- Incyte Corporation$8K
- Blueprint Medicines Corporation$7K
- Spark Therapeutics, Inc.$6K
- Jazz Pharmaceuticals Inc.$6K
- plus $24K from 11 others
Across 56 payments — averaging $4790.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$144K
- Astellas Pharma Global Development$55K
- Autolus Inc$31K
- Amgen$22K
- Daiichi Sankyo Inc.$17K
What the payments were for
- Consulting fees$43,07757%
- Speaking & faculty fees$24,36732%
- Travel & lodging$5,7898%
- Food & beverage$2,5933%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 4 | $14,216 |
| Biomarin Pharmaceutical Inc. | 11 | $10,649 |
| Incyte Corporation | 7 | $7,837 |
| Blueprint Medicines Corporation | 5 | $7,077 |
| Spark Therapeutics, Inc. | 7 | $6,222 |
| Jazz Pharmaceuticals Inc. | 9 | $5,604 |
| Sobi, Inc | 5 | $5,511 |
| Syndax Pharmaceuticals, Inc. | 7 | $4,771 |
| Novartis | 4 | $4,021 |
| Sanofi | 1 | $2,996 |
| Pfizer | 6 | $2,152 |
| CTI Biopharma Corp. | 1 | $1,725 |
| AbbVie | 3 | $1,349 |
| National Marrow Donor Program | 2 | $974 |
| Bristol Myers Squibb | 3 | $574 |
| Genentech, Inc. | 1 | $177 |
| Astellas Pharma US Inc | 2 | $89 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$75,945 in reported general payments places this provider in the 90th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 129 | $1,681,386 |
| PromactaEltrombopag Olamine | 28 | $583,555 |
| SprycelDasatinib | 41 | $527,475 |
| BesremiRopeginterferon Alfa-2b-Njft | 26 | $397,348 |
| RevlimidLenalidomide | 21 | $343,069 |
| RezurockBelumosudil Mesylate | 13 | $217,425 |
| EliquisApixaban | 98 | $101,214 |
| VenclextaVenetoclax | 53 | $54,761 |
| PegasysPeginterferon Alfa-2a | 12 | $52,208 |
| XareltoRivaroxaban | 20 | $29,923 |
| Ursodiol | 37 | $4,575 |
| Enoxaparin Sodium | 13 | $4,019 |
| Voriconazole | 26 | $3,467 |
| Tacrolimus | 25 | $2,509 |
| Hydroxyurea | 99 | $2,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $7,837 | $1,681,386129 claims |
| NovartisPromacta | $4,021 | $583,55528 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $14,216 | $527,47541 claims |
| Bristol Myers SquibbRevlimid | $574 | $343,06921 claims |
| PfizerEliquis | $2,152 | $101,21498 claims |
| AbbVieVenclexta | $1,349 | $54,76153 claims |
| Genentech, Inc.Pegasys | $177 | $52,20812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Omaha
- Mojtaba AkhtariOmaha$1.8M
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Vijaya BhattOmaha$58K
- Samer RennoOmaha$41K
- Timothy DoriusOmaha$24K
- Stefano TarantoloOmaha$13K
- Marcel DevettenOmaha$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.